Conditions: Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 300
Healthy volunteers: no

Brief summary:
In this randomised, double-blind, parallel group trial, the safety and efficacy of 5 mg of Linagliptin administered orally once daily will be compared with a placebo after 24 weeks of treatment in monotherapy in patients with type 2 diabetes and insufficient glycaemic control.

Detailed description:

Arms:
arm 1: once a day arm 2: once a day

Interventions: intervention 1: Placebo intervention 2: Linagliptin
Intervention descriptions: intervention 1: once a day intervention 2: once a day

Protocol document: